Crohn's Disease Clinical Trials

31 trials recruiting in Canada.

Digestive Health

Recruiting Drug Device Behavioral Older adults Healthy volunteers

22 trials

Comparing Mirikizumab - with LY4395089 for crohn disease

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Mirikizumab - Intravenous (IV) and Mirikizumab - Subcutaneous (SC). Group B receives LY4395089, together with one or more of: Mirikizumab - Intravenous (IV) and Mirikizumab - Subcutaneous (SC).

Sites in Greenfield Park, Lethbridge and 2 more cities

Phase 2
2 groups
Sites in Greenfield Park, Lethbridge and 2 more cities
Recruiting

Official title: A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Crohn Disease · Eli Lilly and Company

Comparing Tirzepatide with Mirikizumab for Crohn's disease

Explore this study →

There are 2 groups in this study. Group A receives Mirikizumab and Tirzepatide. Group B receives Mirikizumab and Placebo.

Sites in London, Vancouver and 3 more cities

Phase 3
2 groups
Sites in Edmonton, London and 3 more cities
Recruiting

Official title: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease · Eli Lilly and Company

Comparing Guselkumab with Risankizumab for crohn disease

Explore this study →

There are 2 groups in this study. Group A receives Guselkumab. Group B receives Risankizumab.

Sites in Montreal, Edmonton and 5 more cities

Phase 3
2 groups
Sites in Edmonton, Vancouver and 5 more cities
Recruiting

Official title: A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease · Janssen Research & Development, LLC

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for crohn's disease.

Comparing JNJ-78934804 with Guselkumab for crohn disease

Explore this study →

There are 2 groups in this study. Group A receives JNJ-78934804. Group B, the comparison group, receives Guselkumab, together with one or more of: JNJ-78934804.

Sites in Edmonton, Montreal and 7 more cities

Phase 3
2 groups
Sites in Edmonton, Vancouver and 7 more cities
Recruiting

Official title: A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease · Janssen Research & Development, LLC

Testing Icotrokinra against a placebo for crohn disease

Explore this study →

There are 8 groups in this study. Groups A, B, D, F and G receive Icotrokinra. Groups C and E, the placebo group, receive Placebo. Group H, the placebo group, receives Placebo, together with one or more of: Icotrokinra.

Sites in Edmonton, Barrie and 6 more cities

Phase 2
8 groups
Sites in Edmonton, Vancouver and 6 more cities
Recruiting

Official title: A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease · Janssen Research & Development, LLC

Testing IV Tulisokibart against a placebo for Crohn's disease

Explore this study →

There are 11 groups in this study. Group A receives one or more of: IV Tulisokibart and SC Tulisokibart. Groups B and C receive one or more of: IV Tulisokibart, SC Tulisokibart and SC Placebo. Groups D and I, the placebo group, receive one or more of: IV Tulisokibart, IV Placebo and SC Placebo. …and 4 more groups.

Sites in London, Montreal and 13 more cities

Phase 3
11 groups
Sites in Calgary, Edmonton and 13 more cities
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease · Merck Sharp & Dohme LLC

Comparing 4 approaches for Crohn's disease

Explore this study →

There are 4 groups in this study. Groups A and B receive TAK-279, together with one or more of: Placebo. Group C receives TAK-279. Group D receives Placebo.

Sites in London, Montreal and 4 more cities

Phase 2
4 groups
Sites in Calgary, New Westminster and 4 more cities
Recruiting

Official title: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · Takeda

Comparing 22 approaches for Crohn's disease

Explore this study →

There are 22 groups in this study. Groups A, B, K and L receive Risankizumab. Groups C, D, E and F receive Trosunilimab. Groups G, H, I and J receive Risankizumab and Trosunilimab. …and 2 more groups.

One site, in Québec

Phase 2
22 groups
One site, in Québec
Recruiting

Official title: Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Crohn's Disease · AbbVie

Testing Mirikizumab for crohn disease

Explore this study →

Everyone in this study is in one group and receives Mirikizumab.

Sites in Hamilton, London and 2 more cities

Phase 4
1 group
Sites in Vancouver, Hamilton and 2 more cities
Recruiting

Official title: Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

Crohn Disease · Alimentiv Inc.

Testing Afimkibart against a placebo for moderately to severely active crohns disease

Explore this study →

There are 2 groups in this study. Group A receives Afimkibart. Group B, the placebo group, receives Placebo.

Sites in London, Barrie and 3 more cities

Phase 3
2 groups
Sites in Barrie, Brampton and 2 more cities
Recruiting

Official title: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Moderately to Severely Active Crohns Disease · Hoffmann-La Roche

Comparing 3 approaches for crohn disease

Explore this study →

There are 3 groups in this study. Group A, the comparison group, receives one or more of: TNFa Antagonist - Infliximab and TNFa Antagonist - Adalimumab. Group B, the comparison group, receives one or more of: Anti-IL12/23 or anti-IL23 - Ustekinumab and Anti-IL12/23 or anti-IL23 - Risankizumab. Group C, the comparison group, receives one or more of: Anti-integrin - Vedolizumab IV and Anti-integrin - Vedolizumab IV and SC.

Sites in Montreal, Brampton and 14 more cities

Phase 4
3 groups
Sites in Calgary, Edmonton and 14 more cities
Recruiting

Official title: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Crohn Disease · University of Calgary

Testing Duvakitug against a placebo for Crohn's disease

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Duvakitug. Group D, the placebo group, receives Placebo.

Sites in Edmonton, Hamilton and 3 more cities

Phase 3
4 groups
Sites in Edmonton, Hamilton and 3 more cities
Recruiting

Official title: A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · Sanofi

Testing Duvakitug against a placebo for Crohn's disease

Explore this study →

There are 3 groups in this study. Groups A and B receive Duvakitug. Group C, the placebo group, receives Placebo.

Sites in London, Montreal and 7 more cities

Phase 3
3 groups
Sites in Oakville, Brampton and 7 more cities
Recruiting

Official title: An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · Sanofi

Testing Afimkibart against a placebo for moderately to severely active crohns disease

Explore this study →

There are 3 groups in this study. Groups A and B receive Afimkibart. Group C, the placebo group, receives Placebo.

Sites in Edmonton, Trois-Rivières and 1 more city

Phase 3
3 groups
Sites in Edmonton, Vaughan and 1 more city
Recruiting

Official title: A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Moderately to Severely Active Crohns Disease · Hoffmann-La Roche

TIDHI Mental Health in IBD Patients Study

Explore this study →

There are 2 groups in this study. Group A receives Healing Circuits™ sessions. Group B receives self-directed Healing Circuits™ curriculum.

One site, in North York

2 groups
Recruiting

Crohn Disease (CD) · TIDHI Innovation Inc.

Comparing 8 approaches for Crohn's disease

Explore this study →

There are 8 groups in this study. Groups A and H receive Risankizumab. Groups B and G receive Risankizumab and Trosunilimab. Group C receives Trosunilimab. …and 3 more groups.

Sites in Edmonton, Calgary and 5 more cities

Phase 2
8 groups
Sites in Calgary, Edmonton and 5 more cities
Recruiting

Official title: Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Crohn's Disease · AbbVie

Comparing 3 approaches for Crohn's disease

Explore this study →

There are 3 groups in this study. Group A receives Vedolizumab and Adalimumab. Group B receives Vedolizumab and Ustekinumab. Group C receives Vedolizumab.

Sites in Edmonton, London and 5 more cities

Phase 4
3 groups
Sites in Edmonton, London and 4 more cities
Recruiting

Official title: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Crohn's Disease · Takeda

Testing Ustekinumab for crohn disease (CD)

Explore this study →

There are 2 groups in this study. Group A receives Ustekinumab 90 mg SC q8w. Group B receives Ustekinumab 90 mg SC q12w.

One site, in Montreal

Phase 4
2 groups
One site, in Montreal
Recruiting

Official title: De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Crohn Disease (CD) · McGill University Health Centre/Research Institute of the McGill University Health Centre

Testing SAR441566 against a placebo for Crohn's disease

Explore this study →

There are 4 groups in this study. Groups A, B and C receive SAR441566. Group D, the placebo group, receives SAR441566 matching Placebo.

Sites in Calgary, Montreal and 1 more city

Phase 2
4 groups
Sites in Calgary, Montreal and 1 more city
Recruiting

Official title: A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Crohn's Disease · Sanofi

Comparing KleanLyte with Bi-PegLyte for crohn disease

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives KleanLyte. Group B, the comparison group, receives Bi-PegLyte.

One site, in Winnipeg

Phase 4
2 groups
One site, in Winnipeg
Recruiting

Official title: Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Crohn Disease · University of Manitoba

Testing Vedolizumab for moderately to severely active Crohn's disease

Explore this study →

There are 2 groups in this study. Groups A and B receive Vedolizumab.

Sites in London, Bridgewater and 3 more cities

Phase 4
2 groups
Sites in Calgary, Edmonton and 3 more cities
Recruiting

Official title: VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Moderately to Severely Active Crohn's Disease · Alimentiv Inc.

Testing Vedolizumab against a placebo for Crohn's disease

Explore this study →

There are 3 groups in this study. Group A receives Vedolizumab and Upadacitinib. Group B, the placebo group, receives Vedolizumab and Placebo. Group C receives Vedolizumab.

Sites in Barrie, Calgary and 7 more cities

Phase 3
3 groups
Sites in Calgary, Winnipeg and 7 more cities
Recruiting

Official title: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Crohn's Disease · Takeda

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Crohn's Disease trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.